Brinker Capital’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
$1.69M Sell
14,858
-196
-1% -$20.8K 0.05% 343
2020
Q1
$1.21M Sell
15,054
-712
-5% -$73.7K 0.05% 368
2019
Q4
$1.68M Sell
15,766
-120
-0.8% -$12.5K 0.05% 362
2019
Q3
$1.7M Sell
15,886
-67,340
-81% -$6.91M 0.06% 349
2019
Q2
$8.47M Sell
83,226
-18,793
-18% -$1.81M 0.31% 67
2019
Q1
$9.17M Buy
102,019
+48,589
+91% +$4.21M 0.35% 57
2018
Q4
$4.45M Sell
53,430
-6,187
-10% -$580K 0.2% 115
2018
Q3
$6.43M Buy
59,617
+1,317
+2% +$144K 0.23% 84
2018
Q2
$6.41M Buy
58,300
+3,775
+7% +$393K 0.25% 81
2018
Q1
$5.47M Sell
54,525
-1,756
-3% -$180K 0.21% 95
2017
Q4
$5.54M Buy
56,281
+12,878
+30% +$1.22M 0.22% 99
2017
Q3
$4.06M Sell
43,403
-5,099
-11% -$541K 0.17% 131
2017
Q2
$5.39M Sell
48,502
-13,151
-21% -$1.39M 0.25% 94
2017
Q1
$6.05M Sell
61,653
-3,186
-5% -$304K 0.28% 66
2016
Q4
$5.96M Buy
64,839
+59,064
+1,023% +$5.09M 0.33% 64
2016
Q3
$491K Buy
+5,775
New +$485K 0.05% 198

Other funds holding DGX

Brinker Capital's DGX Position: Q2 2020 in Review

Brinker Capital reduced its Quest Diagnostics (DGX) stake by 1.3% in Q2 2020, selling an estimated $20.8K and leaving 14,858 shares worth $1.69M. The position accounts for 0.05% of the portfolio, ranked #343.

Brinker Capital first reported a position in DGX in Q3 2016 and has held it in 16 quarters since. The position peaked at $9.17M in Q1 2019. 749 funds tracked by Wall St. Rank hold DGX as of Q2 2020.

  • Brinker Capital held 14,858 shares of Quest Diagnostics worth $1.69M as of Q2 2020.
  • Brinker Capital sold 196 Quest Diagnostics shares in Q2 2020, an estimated $20.8K.
  • Quest Diagnostics made up 0.05% of Brinker Capital's portfolio in Q2 2020, its #343 holding.
  • Brinker Capital first reported a position in Quest Diagnostics in Q3 2016 and has held it in 16 quarters since.
  • Brinker Capital's Quest Diagnostics position peaked at $9.17M in Q1 2019.
  • 749 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.